Palisade Bio (PALI) Gains from Investment Securities (2012 - 2026)
Palisade Bio (PALI) reported Gains from Investment Securities of $254200.0 for Q1 2026, up 184.34% on a QoQ basis from $89400.0 in Q3 2025.
Palisade Bio (PALI) has 14 years of Gains from Investment Securities data on file, last reported at $254200.0 in Q1 2026.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $254200.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254200.0 (changed N/A YoY) and the FY2025 annual result came in at $116600.0, up 130.1% from the prior year.
- Gains from Investment Securities grew to $254200.0 in Q1 2026 per PALI's latest filing, from $89400.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $254200.0 in Q1 2026 and bottomed at -$355000.0 in Q4 2022.
- The 4-year median for Gains from Investment Securities is $59198.5 (2023), against an average of $34511.5.
- The widest annual swing landed in 2022, when Gains from Investment Securities sank 79.68%; it then plunged 97.18% in 2023.
- Tracing PALI's Gains from Investment Securities over 4 years: stood at -$355000.0 in 2022, then soared by 101.29% to $4576.0 in 2023, then jumped by 1853.67% to $89400.0 in 2025, then jumped by 184.34% to $254200.0 in 2026.
- Per Business Quant, the three latest PALI Gains from Investment Securities figures stand at $254200.0 (Q1 2026), $89400.0 (Q3 2025), and $89400.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 254,200.00 |
| Mar 31, 2026 | 254,200.00 |
| Sep 30, 2025 | 89,400.00 |
| Sep 30, 2025 | 89,400.00 |
| Jun 30, 2025 | 89,400.00 |
| Jun 30, 2025 | 89,400.00 |
| Sep 30, 2023 | 4,576.00 |
| Sep 30, 2023 | 4,576.00 |
| Jun 30, 2023 | 28,997.00 |
| Jun 30, 2023 | 28,997.00 |
| Mar 31, 2023 | 2,040.00 |
| Mar 31, 2023 | 2,040.00 |
| Dec 31, 2022 | -355,000.00 |
| Dec 31, 2022 | -355,000.00 |
| Sep 30, 2022 | 162,479.00 |
| Sep 30, 2022 | 162,479.00 |
| Sep 30, 2021 | 799,562.00 |
| Sep 30, 2021 | 799,562.00 |
| Jun 30, 2021 | 84,132.00 |
| Jun 30, 2021 | 84,132.00 |
| Dec 31, 2020 | 826,769.00 |
| Dec 31, 2020 | 826,769.00 |
| Sep 30, 2020 | 1.80 Mn |
| Sep 30, 2020 | 1.80 Mn |
| Jun 30, 2020 | 920,384.00 |
| Jun 30, 2020 | 920,384.00 |
| Dec 31, 2019 | 271,660.00 |
| Dec 31, 2019 | 271,660.00 |
| Sep 30, 2019 | 8.50 Mn |
| Sep 30, 2019 | 8.50 Mn |
| Jun 30, 2019 | 700,000.00 |
| Jun 30, 2019 | 700,000.00 |
| Mar 31, 2019 | 800,000.00 |
| Mar 31, 2019 | 800,000.00 |
| Dec 31, 2018 | -22,342.00 |
| Dec 31, 2018 | -22,342.00 |
| Sep 30, 2018 | 550,215.00 |
| Sep 30, 2018 | 550,215.00 |
| Mar 31, 2018 | 4,000.00 |
| Mar 31, 2018 | 4,000.00 |
| Sep 30, 2017 | 46,982.00 |
| Sep 30, 2017 | 46,982.00 |
| Dec 31, 2016 | -34,121.00 |
| Dec 31, 2016 | -34,121.00 |
| Sep 30, 2016 | 774,083.00 |
| Sep 30, 2016 | 774,083.00 |
| Jun 30, 2016 | 3.81 Mn |
| Jun 30, 2016 | 3.81 Mn |
| Mar 31, 2016 | -14,029.00 |
| Mar 31, 2016 | -14,029.00 |
| Dec 31, 2015 | -14,102.00 |
| Dec 31, 2015 | -14,102.00 |
| Mar 31, 2015 | 357.00 |
| Mar 31, 2015 | 357.00 |
| Dec 31, 2014 | 341,264.00 |
| Dec 31, 2014 | 341,264.00 |
| Dec 31, 2013 | 960,157.00 |
| Dec 31, 2013 | 960,157.00 |
| Sep 30, 2013 | 677,883.00 |
| Sep 30, 2013 | 677,883.00 |
| Jun 30, 2013 | 188,317.00 |
| Jun 30, 2013 | 188,317.00 |
| Mar 31, 2013 | -6,518.00 |
| Mar 31, 2013 | -6,518.00 |
| Dec 31, 2012 | 35.00 |
| Dec 31, 2012 | 35.00 |